{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-020785","form_type":"8-K","ticker":"IMMX","cik":"0001873835","company_name":"Immix Biopharma, Inc.","filed_at":"2024-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.042793+00:00","generated_at":"2026-06-01T13:21:15.332881+00:00","sec_items":["3.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immix Biopharma completes short-form merger of majority-owned subsidiary Nexcella","bullets":["On May 20, 2024, Immix merged its >95%-owned subsidiary Nexcella into itself; Nexcella ceased to exist.","Issued 989,876 shares of common stock to former Nexcella stockholders (including third-party cash investors).","Issued 275,759 restricted stock awards and options to purchase 595,676 shares at $2.47 per share to former Nexcella equity plan participants.","Nexcella stockholders have appraisal rights under Delaware law if they perfect them."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-020785","json":"https://secwatch.observer/filing/0001493152-24-020785.json","markdown":"https://secwatch.observer/filing/0001493152-24-020785.md","text":"https://secwatch.observer/filing/0001493152-24-020785.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873835/000149315224020785/0001493152-24-020785-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873835/000149315224020785/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T13:21:15.332881+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}